Syndax Pharmaceuticals, Inc. (SNDX) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $18.52 (+0.27%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 27, 2026 | Stephen Willey | Stifel Nicolaus | $45.00 | +143.0% |
| Nov 4, 2025 | Peter Lawson | Barclays | $22.00 | +18.8% |
| Jul 15, 2025 | David Dai | UBS | $35.00 | +89.0% |
| Jul 10, 2025 | Corinne Johnson | Goldman Sachs | $18.00 | -2.8% |
| Nov 13, 2024 | George Farmer | Scotiabank | $18.00 | -2.8% |
| Oct 24, 2024 | David Dai | UBS | $37.00 | +99.8% |
| Aug 15, 2024 | Yigal Nochomovitz | Citigroup | $34.00 | +83.6% |
| Aug 15, 2024 | Jason Zemansky | Bank of America Securities | $31.00 | +67.4% |
| Aug 15, 2024 | Peter Lawson | Barclays | $33.00 | +78.2% |
| Jul 30, 2024 | Jason Zemansky | Bank of America Securities | $30.00 | +62.0% |
| Jun 28, 2024 | Kelly Shi | Jefferies | $37.00 | +99.8% |
| May 9, 2024 | Bradley Canino | Stifel Nicolaus | $40.00 | +116.0% |
Top Analysts Covering SNDX
SNDX vs Sector & Market
| Metric | SNDX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.40 |
| Analyst Count | 9 | 8 | 19 |
| Target Upside | +112.4% | +11474.9% | +17.1% |
| P/E Ratio | -6.41 | 3.92 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $77M | $84M | $97M | 6 |
| 2026-09-30 | $85M | $95M | $112M | 4 |
| 2026-12-31 | $100M | $112M | $131M | 5 |
| 2027-03-31 | $61M | $68M | $80M | 3 |
| 2027-06-30 | $61M | $68M | $80M | 3 |
| 2027-09-30 | $61M | $68M | $80M | 3 |
| 2027-12-31 | $61M | $68M | $80M | 3 |
| 2028-12-31 | $704M | $715M | $725M | 9 |
| 2029-12-31 | $786M | $933M | $1.16B | 4 |
| 2030-12-31 | $956M | $1.13B | $1.41B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.85 | $-0.51 | $-0.22 | 7 |
| 2026-09-30 | $-0.52 | $-0.43 | $-0.37 | 3 |
| 2026-12-31 | $-0.28 | $-0.23 | $-0.20 | 3 |
| 2027-03-31 | $-0.69 | $-0.56 | $-0.48 | 3 |
| 2027-06-30 | $-0.67 | $-0.55 | $-0.47 | 2 |
| 2027-09-30 | $-0.54 | $-0.44 | $-0.38 | 2 |
| 2027-12-31 | $-0.55 | $-0.45 | $-0.39 | 2 |
| 2028-12-31 | $-0.35 | $0.76 | $1.98 | 8 |
| 2029-12-31 | $1.49 | $1.87 | $2.47 | 6 |
| 2030-12-31 | $2.36 | $2.96 | $3.91 | 6 |
Frequently Asked Questions
What is the analyst consensus for SNDX?
The consensus among 9 analysts covering Syndax Pharmaceuticals, Inc. (SNDX) is Buy with an average price target of $40.00.
What is the highest price target for SNDX?
The highest price target for SNDX is $45.00, set by Stephen Willey at Stifel Nicolaus on 2026-02-27.
What is the lowest price target for SNDX?
The lowest price target for SNDX is $18.00, set by George Farmer at Scotiabank on 2024-11-13.
How many analysts cover SNDX?
9 analysts have issued ratings for Syndax Pharmaceuticals, Inc. in the past 12 months.
Is SNDX a buy or sell right now?
Based on 9 analyst ratings, SNDX has a consensus rating of Buy (2.00/5) with a +112.4% upside to the consensus target of $40.00.
What are the earnings estimates for SNDX?
Analysts estimate SNDX will report EPS of $-0.51 for the period ending 2026-06-30, with revenue estimated at $84M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.